Neuroendocrine Cancer
(asked on 19th March 2026) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the total amount of Government investment in research into neuroendocrine cancers has been in each of the last ten years; and what specific funding allocations have been made for neuroendocrine cancer within the forthcoming National Cancer Plan.
Government responsibility for delivering cancer research is shared between the Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.
Between financial years 2015/16 and 2024/25, through the NIHR, the Department for Health and Social Care committed approximately £8 million for new research projects, alongside supporting infrastructure, into neuroendocrine cancer. The following table shows a breakdown of the £8 million for new research projects, alongside supporting infrastructure, into neuroendocrine cancer, from 2015/16 to 2024/25:
2015/16 | £882,750.75 |
2016/17 | £1,170,974.89 |
2017/18 | £798,743.56 |
2018/19 | £833,349.43 |
2019/20 | £867,204.19 |
2020/21 | £878,387.61 |
2021/22 | £829,818.37 |
2022/23 | £610,754.01 |
2023/24 | £455,640.58 |
2024/25 | £707,561.31 |
As well as funding research itself, the Department invests significantly in research expertise and capacity, specialist facilities, support services, and collaborations to support and deliver research in England, known as NIHR infrastructure. NIHR infrastructure underpins research. The spend is not directly attributable to specific research studies for the most part, but an estimate is derived based on the number of studies in neuroendocrine cancer against the annual infrastructure spend.
The findings presented are based on point-in-time analysis for 23 March 2026. The data does fluctuate due to changes such as contract variations and updated information regarding financial reconciliations and support activity.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including neuroendocrine cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.